AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Innoplexus has been accepted to NVIDIA Inception Program
Innoplexus will now be a part of NVIDIA Inception Program. A program that is designed to nurture dedicated and exceptional startups who are revolutionizing industries with advances in AI and data science. The Inception Program helps during different stages of product development, prototyping, and deployment.
The formal confirmation came on May 23rd, 2018. It all started when our Co-founder and CTO, Gaurav Tripathi explained about Innoplexus, our products and what we are doing in Deep Learning to Inception program coordinators at GPU Technology Conference in San Francisco. The program owners liked our idea, especially the way we are using Deep Learning to revolutionize the pharmaceutical industry.
After receiving the confirmation of this virtual accelerator program, Gaurav said, “I have been a huge NVIDIA fan from my gaming days (once upon a time in history, I do used to play) and my PC assembling days (used to sell assembled PCs in IITB campus for some quick money). I have seen it grow from a ‘graphic card’ company to the AI giant that it is now and have been looking for a chance to do something with them or get associated in some way.”
Innoplexus will now get a custom set of ongoing benefits like access to NVIDIA global network and the Deep Learning Institute as well as GPU hardware discounts,and early access to state-of-the-art technology. “This is a very supportive opportunity on our way to an European Artificial Intelligence-Champion”, summarizes Gaurav.
The original article was published on NVIDIA.
Featured News
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience.Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
Parexel and Innoplexus Unveil Single Source of COVID-19 Information for
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trialsBOSTON and DURHAM, N.C. and ESCHBORN, Germany,…
New app for cancer patients
Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…
Innoplexus wins Silver Edison Award for OntosightⓇ Explore
Frankfurt, Germany, March 26, 2020 — Innoplexus AG has been honored with the Silver Edison Award 2020 for its proprietary…
AI CTP engine estimated failure for Biogen’s aducanumab
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific…
How can AI be leveraged for Clinical Trial Prediction?
Successful clinical trials occur at a ratio of 1 in 10, costing around $2-$3 billion, with drugs taking 10–12 years…
Innoplexus launches new Blockchain platform for Pharma innovation
If your loved one was diagnosed with a potentially fatal illness, wouldn’t you want all the information possible to be…